Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

1478301

USP

Olanzapine

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C17H20N4S
CAS Number:
132539-06-1
Molecular Weight:
312.43
Beilstein:
7655141
MDL number:
MFCD00866702
UNSPSC Code:
41116107
PubChem Substance ID:
329750606
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

olanzapine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

InChI key

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , DRD3(1814) , DRD4(1815) , HTR2A(3356) , HTR2C(3358)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Olanzapine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Olanzapine and Fluoxetine Capsules
  • Olanzapine Orally Disintegrating Tablets
  • Olanzapine Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1478312

Olanzapine Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478323

Olanzapine Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0001370

Olanzapine, European Pharmacopoeia (EP) Reference Standard

Y0001380

Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard

Y0001392

Olanzapine impurity A, European Pharmacopoeia (EP) Reference Standard

1478334

Olanzapine Related Compound C, United States Pharmacopeia (USP) Reference Standard

BP1060

Olanzapine, British Pharmacopoeia (BP) Reference Standard

Y0002177

Olanzapine embonate for peak identification, CRS, European Pharmacopoeia (EP) Reference Standard

PHR2537

Olanzapine Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2536

Olanzapine Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2538

Olanzapine Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H301,H315,H317,H336

Hazard Classifications

Acute Tox. 3 Oral - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rajendra P Shukla et al.
Journal of neural transmission (Vienna, Austria : 1996), 127(2), 291-299 (2020-01-08)
Olanzapine is a thienobenzodiazepine compound. It is one of the newer types of antipsychotic drugs used in the treatment of schizophrenia and other psychotic disorders. Several methods have been reported for analyzing olanzapine in its pure form or combined with
Mauricio Tohen et al.
Archives of general psychiatry, 60(11), 1079-1088 (2003-11-12)
Despite the longer duration of the depressive phase in bipolar disorder and the frequent clinical use of antidepressants combined with antipsychotics or mood stabilizers, relatively few controlled studies have examined treatment strategies for bipolar depression. To examine the use of
Elizabeth Brunner et al.
BMC pharmacology & toxicology, 14, 38-38 (2013-08-02)
Olanzapine use has been reported during pregnancy and breastfeeding, but there are no controlled clinical trials assessing the safety of olanzapine exposure to infants and fetuses. The purpose of this report was to review and analyze prospective post-marketing cases of
Delia Bishara et al.
Journal of clinical psychopharmacology, 33(3), 329-335 (2013-04-24)
To conduct a systematic review examining the relationships between olanzapine dose, clinical outcome, dopamine occupancy, and plasma concentration; and to evaluate the potential for therapeutic drug monitoring. A search using Embase, Medline, and Pubmed was conducted; and the literature was
Christopher M Hocking et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 22(4), 1143-1151 (2014-02-14)
Newer drugs incorporated in prophylactic regimens for chemotherapy-induced nausea and vomiting (CINV) have resulted in significantly reduced rates of this feared complication of cytotoxic chemotherapy. However, both delayed chemotherapy-induced nausea and breakthrough CINV remain difficult areas of management and require
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service